Aubrey Molgaard, APRN
Payments from drug & device makers
Across 609 payments — averaging $390.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$228K
- Xeris Pharmaceuticals, Inc.$4K
- Sequel Med Tech, LLC$2K
- Novo Nordisk$618
- Insulet Corporation$532
- Dexcom, Inc.$429
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$151,59364%
- Travel & lodging$70,31830%
- Food & beverage$15,5937%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 415 | $228,428 |
| Xeris Pharmaceuticals, Inc. | 19 | $4,127 |
| Sequel Med Tech, LLC | 11 | $1,705 |
| Novo Nordisk | 39 | $618 |
| Insulet Corporation | 16 | $532 |
| Dexcom, Inc. | 20 | $429 |
| Lilly USA, LLC | 18 | $278 |
| Boehringer Ingelheim | 15 | $238 |
| Bayer | 12 | $228 |
| Amgen | 6 | $208 |
| Mannkind Corporation | 4 | $190 |
| Medtronic | 10 | $180 |
| Tandem Diabetes Care, Inc. | 8 | $129 |
| BETA Bionics, Inc. | 7 | $101 |
| Corcept Therapeutics | 3 | $56 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$237,559 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 116 | $123,293 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 62 | $96,544 |
| JardianceEmpagliflozin | 80 | $79,136 |
| Tresiba Flextouch U-200Insulin Degludec | 68 | $69,494 |
| TrulicityDulaglutide | 52 | $59,863 |
| MounjaroTirzepatide | 38 | $39,444 |
| Tresiba Flextouch U-100Insulin Degludec | 70 | $31,447 |
| FarxigaDapagliflozin Propanediol | 25 | $26,692 |
| RybelsusSemaglutide | 14 | $24,431 |
| Gvoke Hypopen 2-PackGlucagon | 35 | $23,446 |
| KerendiaFinerenone | 24 | $21,364 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 26 | $16,743 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 11 | $12,879 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $11,367 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 35 | $9,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $618 | $154,849152 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Insulin Lispro | $278 | $101,443110 claims |
| Boehringer IngelheimJardiance | $238 | $79,13680 claims |
| AstraZenecaFarxiga | $13 | $26,69225 claims |
| BayerKerendia | $228 | $21,36424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.
Other family in Ames
- Karen HunkeAmes$20K
- Stefanie GaticaAnkeny$354K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Tonia AckermanWest Des Moines$17K
- Chi-Ying SageWaterloo$14K
- Amanda GaldiNorth Liberty$14K
- Jaclyn MeisSioux City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.